Literature DB >> 28481803

Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk.

Anna Loch-Wilkinson1, Kenneth J Beath, Robert John William Knight, William Louis Fick Wessels, Mark Magnusson, Tim Papadopoulos, Tony Connell, Julian Lofts, Michelle Locke, Ingrid Hopper, Rodney Cooter, Karen Vickery, Preeti Avinash Joshi, H Miles Prince, Anand K Deva.   

Abstract

BACKGROUND: The association between breast implants and breast implant-associated anaplastic large cell lymphoma (ALCL) has been confirmed. Implant-related risk has been difficult to estimate to date due to incomplete datasets.
METHODS: All cases in Australia and New Zealand were identified and analyzed. Textured implants reported in this group were subjected to surface area analysis. Sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) dating back to 1999 were secured to estimate implant-specific risk.
RESULTS: Fifty-five cases of breast implant-associated ALCL were diagnosed in Australia and New Zealand between 2007 and 2016. The mean age of patients was 47.1 years and the mean time of implant exposure was 7.46 years. There were four deaths in the series related to mass and/or metastatic presentation. All patients were exposed to textured implants. Surface area analysis confirmed that higher surface area was associated with 64 of the 75 implants used (85.3 percent). Biocell salt loss textured (Allergan, Inamed, and McGhan) implants accounted for 58.7 percent of the implants used in this series. Comparative analysis showed the risk of developing breast implant-associated ALCL to be 14.11 times higher with Biocell textured implants and 10.84 higher with polyurethane (Silimed) textured implants compared with Siltex textured implants.
CONCLUSIONS: This study has calculated implant-specific risk of breast implant-associated ALCL. Higher-surface-area textured implants have been shown to significantly increase the risk of breast implant-associated ALCL in Australia and New Zealand. The authors present a unifying hypothesis to explain these observations.

Entities:  

Mesh:

Year:  2017        PMID: 28481803     DOI: 10.1097/PRS.0000000000003654

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  56 in total

Review 1.  Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

Authors:  Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir
Journal:  Plast Surg (Oakv)       Date:  2020-05-21       Impact factor: 0.947

Review 2.  Surgical Treatment of Capsular Contracture (CC): Literature Review and Outcomes Utilizing Implants in Revisionary Surgery.

Authors:  Nicola Zingaretti; Paolo Vittorini; Valentina Savino; Jacopo Claudio Vittorini; Francesco De Francesco; Michele Riccio; Pier Camillo Parodi
Journal:  Aesthetic Plast Surg       Date:  2021-02-04       Impact factor: 2.326

3.  Breast Implant Texturization Does Not Affect the Crosstalk Between MSC and ALCL Cells.

Authors:  Monia Orciani; Miriam Caffarini; Matteo Torresetti; Anna Campanati; Piercamillo Parodi; Giovanni Di Benedetto; Roberto Di Primio
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

4.  The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis.

Authors:  Suzanne Dawn Turner
Journal:  Aesthet Surg J       Date:  2019-01-31       Impact factor: 4.283

5.  Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants.

Authors:  Peter G Cordeiro; Paola Ghione; Andy Ni; Qunying Hu; Nivetha Ganesan; Natasha Galasso; Ahmet Dogan; Steven M Horwitz
Journal:  J Plast Reconstr Aesthet Surg       Date:  2020-01-20       Impact factor: 2.740

Review 6.  Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Authors:  Mark W Clemens; Ryan C DeCoster; Berry Fairchild; Alexander A Bessonov; Fabio Santanelli di Pompeo
Journal:  Semin Plast Surg       Date:  2019-10-17       Impact factor: 2.314

Review 7.  Advising patients about breast implant associated anaplastic large cell lymphoma.

Authors:  Christopher S Parham; Summer E Hanson; Charles E Butler; M Bradley Calobrace; Raylene Hollrah; Terri Macgregor; Mark W Clemens
Journal:  Gland Surg       Date:  2021-01

Review 8.  Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Authors:  P Rastogi; A K Deva; H Miles Prince
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 9.  Breast Implant-Associated Lymphoma.

Authors:  Julian Kricheldorff; Eva Maria Fallenberg; Christine Solbach; Claudia Gerber-Schäfer; Christoph Rancsó; Uwe von Fritschen
Journal:  Dtsch Arztebl Int       Date:  2018-09-21       Impact factor: 5.594

10.  How I treat breast implant-associated anaplastic large cell lymphoma.

Authors:  Neha Mehta-Shah; Mark W Clemens; Steven M Horwitz
Journal:  Blood       Date:  2018-09-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.